Tmunity Announces June 2019 Investor Conference Schedule

Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that Usman Oz Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at an investor conference in June 2019.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, May 23, 2019
Information
Tags: 
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Medicine, Medical specialties, Clinical medicine, Cancer treatments, Virotherapy, Immune system, Immunotherapy, T cell
Geotags: 
United States, NEW YORK, PENNSYLVANIA
⚠generated by AI ↴
Summary
Key Points: 
  • Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that Usman Oz Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at an investor conference in June 2019.
  • Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases.
  • With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005036/en/


Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics
company focused on saving and improving lives by delivering the full
potential of next-generation T cell immunotherapy, today announced that
Usman “Oz” Azam, MD, President and Chief Executive Officer, and members
of the management team plan to participate at an investor conference in
June 2019.

Jefferies 2019 Global Healthcare Conference
Thursday, June 6, 2019
9:30
a.m. ET
New York, NY

About Tmunity Therapeutics

Tmunity is a private clinical-stage biotherapeutics company focused on
saving and improving lives by delivering the full potential of
next-generation T cell immunotherapy to patients with devastating
diseases. Integrating a foundational collaboration with the University
of Pennsylvania (Penn) with the groundbreaking scientific, clinical and
manufacturing expertise and demonstrated track record of its founders
(Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD,
PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new
center of gravity in translational T cell medicine. The company is
developing a diversified portfolio of novel treatments that exhibit
best-in-class control over T cell activation and direction in the body,
with an initial focus in cancer with two programs currently in the
clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories
and production facilities at Penn and its own dedicated cGMP
manufacturing facility in Norristown, PA, to pursue process improvement
and production scale-up in support of clinical development of its T cell
therapies. For more information, visit www.tmunity.com.

Copyright: 
Copyright Business Wire 2019